XCath Raises $30 Million Series C for Neurovascular Robotics Development
XCath has secured $30 million in Series C funding, increasing total funding to $92 million since its inception. The funds will support the development of its Iris robotic system for neuro-endovascular procedures and clinical telerobotic mechanical thrombectomy. The Iris system was previously used in first-in-human procedures for brain aneurysms in November 2025. The company operates from Houston, Texas, and Pangyo, South Korea, and aims to enhance access to advanced neurovascular care globally.
Theia Market Signal Identification - AI Assisted
XCath has raised $30 million in Series C funding, bringing its total funding to $92 million since 2017. The financing will aid in the development of its Iris robotic system for neuro-endovascular procedures and clinical telerobotic mechanical thrombectomy.
In November 2025, the Iris system was utilized in first-in-human procedures for brain aneurysms at The Panama Clinic, marking a significant milestone in neurovascular robotics. XCath is based in Houston, Texas, and Pangyo, South Korea, and is focused on global expansion of neurovascular care. The robotic system remains under development and is not yet commercially available.
Comments